Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Letter

Antimicrobial Resistance in Campylobacter

On This Page
Article Metrics
1
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: Iovine and Blaser (1) write, "This therapeutic use [of enrofloxacin] was withdrawn (2) but is now under appeal" and "Despite the restrictions on enrofloxacin use, emergence of fluoroquinolone-resistant Campylobacter species, with poultry as an important source, has been documented in the United States… Therefore, our conclusion remains: use of enrofloxacin in poultry materially contributed to increase in human infection by fluoroquinolone-resistant Campylobacter species."

These claims propagate the following important errors. First, the therapeutic use of enrofloxacin was not withdrawn. Judge Davidson's order to withdraw the approval was an initial decision, to which exceptions were filed in 2004. A final decision rests with the US Food and Drug Administration Commissioner.

Second, poultry has not been identified as an important source of fluoroquinolone resistance in human Campylobacter isolates. The raw data of the cited Smith et al. article (3) indicate a nonsignificant negative association between chicken consumption and fluoroquinolone resistance in human isolates. Substantial resistance levels in Northern Hemisphere countries with and without enrofloxacin use, which occurred well before fluoroquinolones were ever used in animals (35), also suggest that attribution of such resistance to enrofloxacin is simplistic.

Finally, rational decision-making is based on probable future consequences of a decision, not past history or causes of the current situation. Iovine and Blaser's claim, "Thus the decision to withdraw therapeutic use of enrofloxacin (3) was warranted," is not implied, even if enrofloxacin use caused the emergence of fluoroquinolone resistance. If withdrawing enrofloxacin increases campylobacteriosis from airsacculitis-positive chickens, withdrawal may greatly harm human health. A rational withdrawal decision cannot be justified. In summary, Iovine and Blaser's view that enrofloxacin should be banned is not supported by the data that they have cited or by principles of sound risk management and decision-making.

Top

Louis Anthony Cox*Comments to Author , Dennis Copeland†, and Michael Vaughn†

Author affiliations: *Cox Associates, Denver, Colorado, USA; †Bayer HealthCare, Shawnee, Kansas, USA

Top

References

  1. Iovine  NM, Blaser  MJ. Antimicrobial resistance in Campylobacter. Emerg Infect Dis. 2004;10:1346.PubMed
  2. Vanhoof  R, Vanderlinden  MP, Dierickx  R, Lauwers  S, Yourassowsky  E, Butzler  JP. Susceptibility of Campylobacter fetus subsp. jejuni to twenty-nine antimicrobial agents. Antimicrob Agents Chemother. 1978;14:5536.PubMed
  3. Smith  KE, Besser  JM, Hedberg  CW, Leano  FT, Bender  JB, Wicklund  JH, Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. Investigation Team. N Engl J Med. 1999;340:152532. DOIPubMed
  4. Svedhem  A, Kaijser  B, Sjogren  E. Antimicrobial susceptibility of Campylobacter jejuni isolated from humans with diarrhea and from healthy chickens. J Antimicrob Chemother. 1981;7:3015. DOIPubMed
  5. Hollander  R. [In vitro activity of 23 chemotherapeutic agents against Campylobacter jejuni/coli strains isolated from feces]. Zentralbl Bakteriol Mikrobiol Hyg [A]. 1983;256:196201.PubMed

Top

Cite This Article

DOI: 10.3201/eid1106.040689

Related Links

Top

Table of Contents – Volume 11, Number 6—June 2005

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Louis Anthony Cox, Jr., Cox Associates, 503 Franklin St, Denver, CO 80218, USA; fax: 303-388-0609



Martin J. Blaser, Department of Medicine, NYU School of Medicine, 550 First Ave, OBV-606, New York, NY 10016, USA; fax: 212-263-3969

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external